Cancel
Susan Emeigh Hart
Vice President, Non-Clinical Safety
@
Venatorx Pharmaceuticals
wu3lys.l5pz@14k87wq5.9y3
Sign up to see email
See Linkedin
Known information
- Holds a V.M.D. (Doctor of Veterinary Medicine) from the University of Pennsylvania School of Veterinary Medicine.
- Earned a Ph.D. from The University of Connecticut.
- Received a B.S. in Animal Science from The Pennsylvania State University.
- Is board certified in both Anatomic and Clinical Pathology through the American College of Veterinary Pathologists.
- Is board certified in General Toxicology through the American Board of Toxicology.
- Is a Eurotox Registered Toxicologist (peer recognized expert in toxicology through the UK Registry of Toxicology).
- Serves as an Adjunct Associate Professor (Pathology) at the University of Pennsylvania School of Veterinary Medicine.
- Previously held the position of Director of Experimental Pathology in the Nonclinical Drug Safety (US) department at Boehringer Ingelheim.
- Was Vice President, Preclinical Development at Intrexon Corporation.
- Served as Senior Director, Non-Clinical Development at Auxilium Pharmaceuticals.
- Worked as Senior Director, Safety Assessment at Genaera Corporation.
- Held various roles at AstraZeneca, Bristol-Myers Squibb, DuPont Pharmaceuticals, and Pfizer.
- Has over 25 years of experience in preclinical drug development.
- Has managed non-clinical drug development programs and regulatory submissions (IND through NDA/BLA) for small molecules and monoclonal antibodies.
- Has experience with unusual biopharmaceuticals such as peptides, aminosterols, oligonucleotides, non-antibody, non-recombinant proteins, and gene therapy products.
- Has worked across a wide variety of therapeutic areas, including cardiovascular/metabolic diseases, anti-infectives, oncology, CNS, rheumatology/orthopedics, and ophthalmology.
About Venatorx Pharmaceuticals
Venatorx Pharmaceuticals, founded in June 2010, focuses on developing novel anti-infectives to treat multi-drug-resistant bacterial and hard-to-treat viral infections. Their lead asset, cefepime-taniborbactam, has completed a Phase 3 study for complicated urinary tract infections and is under FDA review.
Report inaccurate information